Recursion: Pioneering TechBio Solutions in Drug Discovery
Published
Dec 17, 2024 1:48PM EST
Najat Khan, Chief R&D Officer and Chief Commercial Officer, and David Hallett, Chief Scientific Officer at Recursion sit down with Nasdaq's Kristina Ayanian to discuss the strategic advantage of the EXAI and Recursion merger and trends that investors should be looking at moving forward.
No transcript available